Kidney Cancer

>

Latest News

PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC
PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC

February 16th 2025

The TiNivo-2 trial found comparable PROs with tivozanib plus nivolumab vs tivozanib monotherapy in advanced clear cell RCC.

Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC
Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC

February 15th 2025

Nivolumab/Cabozantinib Demonstrates Long-Term Efficacy in Advanced RCC
Nivolumab/Cabozantinib Demonstrates Long-Term Efficacy in Advanced RCC

February 15th 2025

Greater responses were observed in a cohort of patients with renal cell carcinoma receiving lenvatinib plus belzutifan vs pembrolizumab plus lenvatinib.
Lenvatinib/Belzutifan Exhibits Durable Antitumor Activity/Safety in ccRCC

February 15th 2025

Investigators of a phase 2 study will continue to assess long-term efficacy and quality-of-life outcomes in those who receive lenvatinib/pembrolizumab.
Perioperative Lenvatinib Combo Shows Activity in Advanced Clear Cell RCC

February 15th 2025

Video Series
Video Interviews
Podcasts
Two oncologists discuss the impact of advocacy in kidney cancer research, highlighting collaboration between researchers, advocates, and physicians.
Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

More News